Goldman Sachs Group Inc Janux Therapeutics, Inc. Call Options Transaction History
Goldman Sachs Group Inc
- $605 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding JANX
# of Institutions
166Shares Held
37.6MCall Options Held
85.3KPut Options Held
654K-
Ra Capital Management, L.P. Boston, MA9.17MShares$426 Million5.81% of portfolio
-
Janus Henderson Group PLC London, X02.52MShares$117 Million0.06% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.4MShares$112 Million3.93% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$109 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.08MShares$96.5 Million0.17% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $1.94B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...